Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers
about
sameAs
Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and realityCyclooxygenase-1 as the main source of proinflammatory factors after sodium orthovanadate treatmentBiological activity of celecoxib in the bronchial epithelium of current and former smokers.Cannabinoids and cancer: pros and cons of an antitumour strategy.A weighty problem: metabolic perturbations and the obesity-cancer link.Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signalingPersonalizing lung cancer prevention through a reverse migration strategy.Relationship between the expression of cyclooxygenase-2 and survivin in primary pterygium.Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.Direct Sequencing of Cyclooxygenase-2 (COX-2) Revealed an Intronic Variant rs201231411 in Iranian Patients with Pancreatic Cancer.Knockdown of RARB2 identifies a dual role in cancer.Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.Gene expression alterations during HGF-induced dedifferentiation of a renal tubular epithelial cell line (MDCK) using a novel canine DNA microarray.Store-operated Ca2+ Entry Facilitates the Lipopolysaccharide-induced Cyclooxygenase-2 Expression in Gastric Cancer Cells.
P2860
Q28166312-46CA5C53-627B-495E-8490-16F9F8575987Q28652149-04183396-5034-4C49-A076-17A34DC25216Q33640402-8911A6F0-CDFD-48A0-8FEB-3457796BD219Q35100892-1C328770-4957-4219-99B9-6E7599AD55FCQ35689545-F1AC6BE9-13BE-4CAE-A4AB-0DCE2977B236Q36095128-3A8BF58C-53CF-4CA6-B98E-064D43B3BEADQ36561975-A99CA50C-4CFE-474F-A756-636A63254197Q37080513-5838FE4D-E0F3-42BE-9CB5-75A35AE1B837Q37110100-D4FAE313-293D-4B08-861D-0FA76A6FB676Q37732019-E9C5B7F9-CE84-49BB-AF18-09E3F83CDE2DQ39047374-78F41BE0-454C-438E-A0F6-1A37BDDAB203Q39531093-F8ACE8E8-A3A8-4DA6-B65D-2CC0C91BF133Q40370999-4AFC9133-4699-483B-AB32-DFFBF5EEC0B2Q40609070-8D10D591-52FA-4928-86AB-0AA8A42D3DF4Q42379006-60264A6C-2FF3-4385-B855-9D4467B2BDC8
P2860
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@ast
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@en
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@nl
type
label
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@ast
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@en
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@nl
prefLabel
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@ast
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@en
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@nl
P2093
P356
P1476
Characterization of cyclooxyge ...... hibitors in epithelial cancers
@en
P2093
A J Dannenberg
B M Woerner
J L Harmon
J L Masferrer
R A Soslow
P356
10.1054/PLEF.2001.0335
P407
P577
2002-01-01T00:00:00Z